Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,629Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M5,629EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.9Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %2.2PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M44,600,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with VHT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VHTKen Fisher 2016-03-31 Sold Out $114.49 - $132.88
($121.69)
$ 126.214%Sold Out0
VHTKen Fisher 2015-12-31 Buy $123.27 - $134.76
($130.49)
$ 126.21-3%New holding1,808
VHTKen Fisher 2013-12-31 Buy $91.43 - $97.64
($95.51)
$ 126.2132%New holding3,028
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VHT is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VHT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dubuc, PhilippeSenior Officer 2016-04-08Buy1,700$1.996242.71view
Dubuc, PhilippeSenior Officer 2016-04-08Buy3,300$26211view
PAMPLIN, Ann-Marie MichelleDeemed Insider - 6 Months before becoming Insider 2016-04-08Buy10,000$0.1584046.67view
Williams, Allan WilliamSenior Officer 2016-04-08Buy108,500$0.11114645.45view
Stefura, Naomi MarieSenior Officer 2016-04-08Sell4,200$14.6764.52view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell800$20.78507.41view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell400$20.77507.7view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell300$20.75508.29view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell100$20.72509.17view
Gentiletti, NelsonDirector or Senior Officer of Insider or Subsidiar 2016-04-08Sell900$20.7509.76view

Quarterly/Annual Reports about VHT:

    News about VHT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Johnson & Johnson’s 1Q16 Valuation Cheat Sheet Apr 29 2016
    What Developments Did Merck & Co. See during 1Q16? Apr 28 2016
    17 Healthcare ETFs Investors Should Check Up On Apr 28 2016
    UnitedHealth Solid Q1 Earnings Put These ETFs in Focus Apr 21 2016
    Healthcare ETFs to Buy on Blockbuster J&J Q1 Results Apr 20 2016
    ETF Flows: Health Care ETFs Are Shedding Assets in 2016 (FXH, XLV) Apr 19 2016
    2016 Investment Landscape: Right Sector at the Right Time Apr 19 2016
    Existing Chemotherapy Drugs for Lymphoma Apr 07 2016
    Will 2016 See Continued Healthcare Mergers and Acquisitions? Apr 07 2016
    The Zacks Analyst Blog Highlights: Allergan, Pfizer, Health Care Select Sector SPDR Fund, iShares... Apr 07 2016
    Business Cycle Perspective: Has the Healthcare Sector Hit Bottom? Mar 31 2016
    Biotech Stocks Offer a Greater Risk-to-Reward Trade-Off Mar 31 2016
    What Analysts Are Recommending Now for Baxter International Mar 21 2016
    VHT Vs. XLV: Comparing Health Care ETFs Mar 09 2016
    The Zacks Analyst Blog Highlights: SPDR S&P Health Care Services ETF, Health Care Select Sector SPDR... Mar 09 2016
    Trump Healthcare Reforms: Will ETFs Gain Health or Suffer? Mar 08 2016
    Drug Patent Expirations: $190 Billion Is Up for Grabs Mar 03 2016
    Will Generic Drugs Help Curb Healthcare Costs? Mar 02 2016
    Key Products Drove Pfizer’s Growth in 4Q15 Feb 16 2016
    Aetna’s Commercial Enrollments Declined by 0.11 Million in 4Q15 Feb 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)